Tesaro
GSK acquires oncology firm Tesaro for $5.1 billion
January 23, 2019Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer
British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …
GSK to acquire oncology biotech Tesaro for $5.1 billion
December 3, 2018Sales and Marketing GSK, GlaxoSmtihKline, Tesaro, acquisition, oncology, pharma
GlaxoSmithKline is set to acquire US-based oncology biotech Tesaro after both companies signed a definitive agreement with an aggregate cash …
New PARP inhibitor hits UK market, offering distinct advantage
December 18, 2017Sales and Marketing AstraZeneca, Novartis, Tesaro, Zejula, biotech, drugs, lynparza, pharma, pharmaceutical
Tesaro’s Zejula has been launched in the UK but availability on the NHS has still not been decided. The PARP …
Tesaro secures EU approval in specific ovarian cancer population
November 23, 2017Sales and Marketing Europe, European Commission, Tesaro, Zejula, pharma
The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged. Zejula is a poly (ADP-ribose) …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Tesaro’s niraparib hits primary goal in late-stage trials for ovarian cancer trial; shares jump
June 30, 2016Research and Development, Sales and Marketing Tesaro, drug trial, niraparib, ovarian cancer
Shares in Tesaro (Nasdaq: TSRO) jumped to more than double after the company reported late-stage trials for its drug to …
Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million
April 6, 2016Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research
Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
Latest content
FibroFind appoints Lee Borthwick as CEO
